← Back to Search

Photochromic Contact Lens

Light-Adaptive Contact Lenses for Visual Impairment

N/A
Recruiting
Research Sponsored by Nova Southeastern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Experience glare and light sensitivity that impacts patient's daily living activities
Have confirmed diagnosis of ocular condition including but not limited to Stargardt's, Cone dystrophy, Cone-rod dystrophy, Albinism, Retinitis Pigmentosa and Achromatopsia
Must not have
Have current/recent ocular infection, inflammation, surgery in the past 3 months that contraindicates contact lens wear
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measure change from baseline at the 6 week follow-up visit
Awards & highlights
No Placebo-Only Group

Summary

This trial tested whether contact lenses with special technology can ease visual issues for people with vision problems.

Who is the study for?
This trial is for individuals who experience glare and light sensitivity due to conditions like Stargardt's, Cone dystrophy, or Albinism. Participants must be impacted in their daily activities by these issues, able to wear contact lenses, give informed consent, and understand English. Pregnant individuals or those with recent eye infections or surgeries are excluded.
What is being tested?
The study is testing Acuvue Oasys with Transitions contact lenses to see if they can improve visual comfort by reducing glare and light sensitivity for people with visual impairments.
What are the potential side effects?
While the specific side effects aren't listed here, typical contact lens use may cause discomfort, dry eyes, redness or potential infection especially if not used as instructed.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I experience glare and light sensitivity that affects my daily activities.
Select...
I have a diagnosed eye condition like Stargardt's or Retinitis Pigmentosa.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had eye problems or surgery in the last 3 months that prevent me from wearing contact lenses.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measure change from baseline at the 6 week follow-up visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and measure change from baseline at the 6 week follow-up visit for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Glare test
Secondary study objectives
Visual Activities Questionnaire on Glare and Light sensitivity visual functions

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment groupExperimental Treatment1 Intervention
All participants will be fit with Acuvue Oasys with Transitions.

Find a Location

Who is running the clinical trial?

Nova Southeastern UniversityLead Sponsor
99 Previous Clinical Trials
11,958 Total Patients Enrolled
American Academy of OptometryOTHER
5 Previous Clinical Trials
277 Total Patients Enrolled
So Yeon Lee, ODStudy ChairNova Southeastern University

Media Library

Acuvue Oasys with Transitions (Photochromic Contact Lens) Clinical Trial Eligibility Overview. Trial Name: NCT05829135 — N/A
Photophobia Research Study Groups: Treatment group
Photophobia Clinical Trial 2023: Acuvue Oasys with Transitions Highlights & Side Effects. Trial Name: NCT05829135 — N/A
Acuvue Oasys with Transitions (Photochromic Contact Lens) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05829135 — N/A
~8 spots leftby May 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top